PubMed Health treatment related to Hemophilia: 63
The main treatment for hemophilia is called replacement therapy . Concentrates of clotting factor VIII (for hemophilia A) or clotting factor IX (for hemophilia B) are slowly dripped or injected into a vein . These infusions help replace the clotting factor that's missing or low. Clotting factor concentrates can be made from human blood . The blood is treated to prevent the spread of diseases, such as hepatitis . With the current methods of screening and treating donated blood, the risk of getting an infectious disease from human clotting factors is very small. To further reduce the risk, you or your child can take clotting factor concentrates that aren't made from human blood . These are called recombinant clotting factors . Clotting factors are easy to store, mix, and use at home—it only takes about 15 minutes to receive the factor. You may have replacement therapy on a regular basis to prevent bleeding . This is called preventive or prophylactic (PRO-fih-lac-tik) therapy. Or, you may only need replacement therapy to stop bleeding when it occurs. This use of the treatment , on an as-needed basis, is called demand therapy. Demand therapy is less intensive and expensive than preventive therapy. However, there's a risk that bleeding will cause damage before you receive the demand therapy.
Drugs for Hemophilia (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):
(show top 50)
(show all 275)
# |
|
Name |
Status |
Phase |
Clinical Trials |
Cas Number |
PubChem Id |
1 |
|
Rituximab |
Approved |
Phase 4 |
|
174722-31-7 |
|
Synonyms:
ABP-798
ANTICD20
CT-P10
HS006
HS-006
HS-006 (RITUXIMAB BIOSIMILAR)
HSDB 7455|IDEC-C2B8|MabThera®|Rituxan®
IDEC-102
IDEC-C2B8
IG GAMMA-1 CHAIN C REGION
Ig gamma-2A chain C region, membrane-bound form
MABTHERA
MABTHERA RITUXAN
|
R-105 IDEC-102
radiolabeled murine anti-CD20
RG-105
RHCACD20MA
RITUXAN
RITUXIMAB
rituximab-abbs
rituximab-arrx
rituximab-pvvr
SAIT101
SAIT-101
Zevalin
|
|
2 |
|
Prednisone |
Approved, Vet_approved |
Phase 4 |
|
53-03-2 |
5865 |
Synonyms:
1,2-Dehydrocortisone
1,4-Pregnadiene-17a,21-diol-3,11,20-trione
1,4-Pregnadiene-17alpha,21-diol-3,11,20-trione
1,4-Pregnadiene-17α,21-diol-3,11,20-trione
17,21-Dihydroxypregna-1,4-diene-3,11,20-trione
Acis brand OF prednisone
Acsis, prednison
Adasone
Ancortone
Apo-prednisone
Apotex brand OF prednisone
Aventis brand OF prednisone
Betapar
Bicortone
Cartancyl
Colisone
Cortan
Cortancyl
Cortidelt
Cotone
Cutason
Dacorten
Dacortin
Decortancyl
Decortin
Decortisyl
Dehydrocortisone
Dekortin
Delcortin
Dellacort
Dellacort A
Delta Cortelan
Delta E
Delta-cortelan
Deltacortene
delta-Cortisone
Deltacortisone
Deltacortone
Delta-cortone
DELTA-DOME
Deltasone
Deltison
Deltisona
Deltisone
Deltra
Diadreson
Di-Adreson
Diba brand OF prednisone
Econosone
Encorton
Encortone
Enkortolon
Enkorton
Fawns and mcallan brand OF prednisone
FERNISONE
Ferring brand OF prednisone
Fiasone
GALENpharma brand OF prednisone
Halsey drug brand OF prednisone
Hexal brand OF prednisone
Hoechst brand OF prednisone
Hostacortin
ICN brand OF prednisone
Incocortyl
In-Sone
Juvason
Kortancyl
Lichtenstein brand OF prednisone
|
Liquid pred
Lisacort
LODOTRA
Lodotra®|Sterapred®
Me-Korti
Merck brand OF prednisone
Merz brand OF prednisone
Metacortandracin
Meticorten
Mibe brand OF prednisone
Nisona
Nizon
Novoprednisone
NSC-10023
Nurison
Orasone
Origen Prednisone
Panafcort
Panasol
PARACORT
Parmenison
Pehacort
Pharmacia brand OF prednisone
PRD
Precort
Predeltin
PREDN
Predni tablinen
PREDNICEN-M
Prednicorm
Prednicort
Prednicot
Prednidib
Prednilonga
Predniment
Prednison
Prednison acsis
Prednison galen
Prednison hexal
Prednisona
Prednisona [INN-Spanish]
Prednisone
PREDNISONE INTENSOL
PREDNISONE TABLETS
Prednisonum
Prednisonum [INN-Latin]
Prednitone
Prednizon
Prednovister
Presone
Pronison
Pronisone
RAYOS
Rectodelt
Retrocortine
Schering-plough brand OF prednisone
Seatrace brand OF prednisone
SERVISONE
Solvay brand OF prednisone
Sone
Sterapred
Supercortil
Trommsdorff brand OF prednisone
Ultracorten
Ultracortene
Winpred
Wojtab
Zenadrid
|
|
3 |
|
Anti-inhibitor coagulant complex |
Approved, Investigational |
Phase 4 |
|
|
|
Synonyms:
Activated prothrombin complex concentrate
Antiinhibitor coagulant complex
ANTI-INHIBITOR COAGULANT COMPLEX
Factor VIII bypassing fraction
|
Factor VIII inhibitor bypassing activity
Factor VIII inhibitor bypassing fraction
FEIBA
|
|
4 |
|
Thrombin |
Approved, Investigational |
Phase 4 |
|
|
|
Synonyms:
coagulation factor II
THROMBIN
Thrombin bovine
|
Thrombin, Topical (Bovine)
THROMBOSTAT
|
|
5 |
|
Ropivacaine |
Approved |
Phase 4 |
|
84057-95-4 |
71273 175805 |
Synonyms:
(-)-1-Propyl-2',6'-dimethyl-2-piperidylcarboxyanilide
(-)-1-Propyl-2',6'-pipecoloxylidide
(+-)-Ropivacaine
(S)-(-)-1-Propyl-2',6'-pipecoloxylidide
(S)-(−)-1-PROPYL-2',6'-PIPECOLOXYLIDIDE
(S)-ROPIVACAINE
1 Propyl 2',6' pipecoloxylidide
1-Propyl-2',6'-dimethyl-2-piperidylcarboxyanilide
1-Propyl-2',6'-pipecoloxylidide
1-propyl-2',6'-pipecoloxylidide|AL-381|LEA-103|Naropin®|ropivacaine hydrochloride
AL-381
DL-Ropivacaine
LEA 103
LEA-103
L-N-N-Propylpipecolate-2,6-xylidide
L-N-N-Propylpipecolic acid-2,6-xylidide
Naropeine
|
Naropin
N-N-Propylpipecolate-2,6-xylidide
N-N-Propylpipecolic acid-2,6-xylidide
Racemic ropivacaine
rac-Ropivacaine
Ropivacaina
Ropivacaina [INN-Spanish]
Ropivacaina [Spanish]
Ropivacaine
Ropivacaine [INN]
Ropivacaine hydrochloride
Ropivacaine monohydrochloride
Ropivacaine monohydrochloride, (S)-isomer
Ropivacainum
Ropivacainum [INN-Latin]
S-Ropivacaine
|
|
6 |
|
Triamcinolone |
Approved, Vet_approved |
Phase 4 |
|
124-94-7 |
31307 |
Synonyms:
11b,16a,17a,21-Tetrahydroxy-9a-fluoro-1,4-pregnadiene-3,20-dione
11beta,16alpha,17alpha,21-Tetrahydroxy-9alpha-fluoro-1,4-pregnadiene-3,20-dione
11Β,16α,17α,21-tetrahydroxy-9α-fluoro-1,4-pregnadiene-3,20-dione
9a-Fluoro-11b,16a,17,21-tetrahydroxypregna-1,4-diene-3,20-dione
9a-Fluoro-11b,16a,17a,21-tetrahydroxypregna-1,4-diene-3,20-dione
9a-Fluoro-16a-hydroxyprednisolone
9alpha-Fluoro-11beta,16alpha,17,21-tetrahydroxypregna-1,4-diene-3,20-dione
9alpha-Fluoro-11beta,16alpha,17alpha,21-tetrahydroxypregna-1,4-diene-3,20-dione
9alpha-Fluoro-16alpha-hydroxyprednisolone
9-Fluoro-11b,16a,17,21-tetrahydroxypregna-1,4-diene-3,20-dione
9-Fluoro-11beta,16alpha,17,21-tetrahydroxypregna-1,4-diene-3,20-dione
9-Fluoro-11β,16α,17,21-tetrahydroxypregna-1,4-diene-3,20-dione
9Α-fluoro-11β,16α,17,21-tetrahydroxypregna-1,4-diene-3,20-dione
9Α-fluoro-11β,16α,17α,21-tetrahydroxypregna-1,4-diene-3,20-dione
9Α-fluoro-16α-hydroxyprednisolone
Adcortyl
Aristocort
ARISTOCORT A
Aristocort Tablets
Aristogel
Aristospan
Azmacort
Celeste
Cinolone
Cinolone-T
DELPHICORT
Fluoxiprednisolone
fluoxiprednisolone|Kenalog®|Nasacort®
Fluoxyprednisolone
Flutex
Fougera
Kenacort
Kenacort-A
Kenacort-Ag
KENALOG
Kenalog in Orabase
Kenalog-10
Kenalog-40
Kenalog-H
Ledercort
|
NASACORT
Nasacort Aq
Nasacort Hfa
NSC-13397
Omcilon
Omicilon
Oracort
Oralone
Orion
Polcortolon
Rodinolone
Sk-Triamcinolone
TIAMCINOLONUM
Tiamcinolonum [INN-Latin]
Triacet
Triacort
Triamcet
Triamcinalone
Triamcinlon
Triamcinolon
Triamcinolona
Triamcinolona [INN-Spanish]
TRIAMCINOLONE
Triamcinolone acetonide
Triamcinolone diacetate
Triamcinolone hexacetonide
Triamcinolonum
Triamcinolonum [INN]
Triam-Tablinen
Triatex
Tricortale
Triderm
Trilone
Tri-Nasal
Tristoject
Trymex
Vetalog
Volon
Volon A
|
|
7 |
|
Hyaluronic acid |
Approved, Vet_approved |
Phase 4 |
|
9004-61-9 |
53477741 |
Synonyms:
(2S,3S,4R,5R,6R)-3-[(2S,3R,4R,5S,6R)-3-Acetamido-4,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-4,5,6-trihydroxyoxane-2-carboxylate
(2S,3S,4R,5R,6R)-3-[(2S,3R,4R,5S,6R)-3-Acetamido-4,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-4,5,6-trihydroxyoxane-2-carboxylic acid
(2S,3S,4R,5R,6R)-3-{[(2S,3R,4R,5S,6R)-4,5-dihydroxy-3-[(1-hydroxyethylidene)amino]-6-(hydroxymethyl)oxan-2-yl]oxy}-4,5,6-trihydroxyoxane-2-carboxylate
2-Acetamido-2-deoxy-b-D-gluco-hexopyranosyl-(1->4)-b-D-gluco-hexopyranuronate
2-Acetamido-2-deoxy-b-D-gluco-hexopyranosyl-(1->4)-b-D-gluco-hexopyranuronic acid
2-Acetamido-2-deoxy-beta-D-gluco-hexopyranosyl-(1->4)-beta-D-gluco-hexopyranuronate
|
2-Acetamido-2-deoxy-beta-D-gluco-hexopyranosyl-(1->4)-beta-D-gluco-hexopyranuronic acid
2-Acetamido-2-deoxy-β-D-gluco-hexopyranosyl-(1->4)-β-D-gluco-hexopyranuronate
2-Acetamido-2-deoxy-β-D-gluco-hexopyranosyl-(1->4)-β-D-gluco-hexopyranuronic acid
Hyaluronan
Hyaluronate
WURCS=2.0/2,2,1/[a2122a-1b_1-5][a2122h-1b_1-5_2*ncc/3=o]/1-2/a4-b1
|
|
8 |
|
Benzocaine |
Approved, Investigational |
Phase 4 |
|
1994-09-7, 94-09-7 |
2337 |
Synonyms:
(P-(Ethoxycarbonyl)phenylamine
4-(Ethoxycarbonyl)aniline
4-(Ethoxycarbonyl)phenylamine
4-Aminobenzoate
4-Aminobenzoate ethyl ester
4-Aminobenzoic acid
4-Aminobenzoic acid ethyl ester
4-Carbethoxyaniline
Acetate, benzocaine
Aethoform
AEZODENT
Amben ethyl ester
Americaine
Anaesthan-syngala
Anaesthesin
Anaesthin
Anestezin
Anesthesin
Anesthesine
Anesthone
ANTHISAN PLUS
AR01
AR-01
Baby anbesol
Bensokain
Benzoak
Benzocaina
BENZOCAINE
Benzocaine acetate
Benzocaine formate
Benzocaine hydrobromide
Benzocaine hydrochloride
Benzocaine methanesulfonate
Benzocainum
BURNEZE
CHILDREN'S CHLORASEPTIC
DEQUACAINE
Dermoplast
Diet ayds
Ethoform
Ethyl 4-aminobenzoate
|
Ethyl 4-aminobenzoic acid
Ethyl aminobenzoate
Ethyl aminobenzoic acid
Ethyl P-aminobenzenecarboxylate
Ethyl p-aminobenzoate
Ethyl p-aminobenzoic acid
Ethyl p-aminophenylcarboxylate
Ethyl p-aminophenylcarboxylic acid
Ethylester kyseliny P-aminobenzoove
Formate, benzocaine
Hurricaine
Hydrobromide, benzocaine
Hydrochloride, benzocaine
Identhesin
Keloform
LANACANE
MEDILAVE
Methanesulfonate, benzocaine
NESTOSYL
Norcain
Norcaine
NSC-41531
NSC-4688
Orabase-b
Ora-jel
ORAJEL
Orthesin
p-(Ethoxycarbonyl)aniline
P-Aminobenzoate
P-Aminobenzoic acid
P-Aminobenzoic acid ethyl ester
Parathesin
Parathesine
p-Carbethoxyaniline
p-Ethoxycarboxylic aniline
Slim mint gum
Solarcaine
Solu H
Topcaine
TYROSOLVEN
TYROZETS
|
|
9 |
|
Tannic acid |
Approved |
Phase 4 |
|
1401-55-4 |
16129878 16129778 |
Synonyms:
Acid, tannic
ácido tánico
Acids, tannic
E181
FEMA NO. 3042
Gallotannic acid
|
Gallotannin
NSC-656273
TANNIC ACID
Tannic acids
Tannins
|
|
10 |
|
Peginterferon alfa-2a |
Approved, Investigational |
Phase 4 |
|
198153-51-4 |
|
Synonyms:
PEGASYS
PEG-IFN alfa-2A
PEG-Interferon alfa-2A
PEGINTERFERON ALFA-2A
PEGYLATED IFN-ALPHA-2A
Pegylated Interfeaon alfa-2A
|
Pegylated interferon alfa-2a
Pegylated interferon alpha-2a
Pegylated-interferon alfa 2a
RO-258310000
ROFERON-A
|
|
11 |
|
Ribavirin |
Approved |
Phase 4 |
|
36791-04-5 |
37542 |
Synonyms:
1-b-D-Ribofuranosyl-1,2,4-triazole-3-carboxamide
1-b-D-Ribofuranosyl-1H-1,2,4-triazole-3-carboxamide
1-beta-D-Ribofuranosyl-1,2,4-triazole-3-carboxamide
1-beta-D-Ribofuranosyl-1H-1,2,4-triazole-3-carboxamide
1-Β-D-ribofuranosyl-1,2,4-triazole-3-carboxamide
1-Β-D-ribofuranosyl-1H-1,2,4-triazole-3-carboxamide
Copegus
Copegus®|RBV|Rebetol®|ribofluranosyl carboxamide|Virazole®
Dermatech brand OF ribavirin
Essex brand OF ribavirin
Grossman brand OF ribavirin
ICN brand OF ribavirin
Merck brand OF ribavirin
NSC-163039
Pfizer brand OF ribavirin
RBV
Rebetol
Rebetron
Rebretron
Ribamide
Ribamidil
Ribamidyl
RIBAPAK
Ribasphere
RIBAV
RIBAVARIN
Ribavirin
|
Ribavirin Capsules
Ribavirin merck brand
Ribavirin Triphosphate
Ribavirina
Ribavirina [INN-Spanish]
Ribavirine
Ribavirine [INN-French]
Ribavirin-TP
Ribavirinum
Ribavirinum [INN-Latin]
RIBOFLURANOSYL CARBOXAMIDE
Ribovirin
RTC
RTCA
RTP
SCH 18908
SCH-18908
Three rivers pharmaceuticals brand OF ribavirin
Tribavirin
Varazid
Vilona
VIRAMID
Viramide
VIRAZID
Virazide
Virazole
Virazole 5'-triphosphate
|
|
12 |
|
Lamivudine |
Approved, Investigational |
Phase 4 |
|
134678-17-4 |
60825 |
Synonyms:
(-)-1-((2R,5S)-2-(Hydroxymethyl)-1,3-oxathiolan-5-yl)cytosine
(-)-2'-Deoxy-3'-thiacytidine
2',3' Dideoxy 3' thiacytidine
2',3'-Dideoxy-3'-thiacytidine
3TC
3'-Thia-2',3'-dideoxycytidine
BCH 189
BCH 189, (-)-
BCH-189
beta-L-2',3'-Dideoxy-3'-thiacytidine
beta-L-3'-Thia-2',3'-dideoxycytidine
b-L-2',3'-Dideoxy-3'-thiacytidine
b-L-3'-Thia-2',3'-dideoxycytidine
Epivir
|
EPIVIR-HBV
Epzicom
GR-109714X
Hepitec
HEPTOVIR
LAMIVUDIN
LAMIVUDINA
LAMIVUDINE
Lamivudine [Usan:Ban:Inn]
Lamivudine, (2S-cis)-isomer
LAMIVUDINUM
ZEFFIX
Β-L-2',3'-dideoxy-3'-thiacytidine
Β-L-3'-thia-2',3'-dideoxycytidine
|
|
13 |
|
Zidovudine |
Approved |
Phase 4 |
|
30516-87-1 |
35370 |
Synonyms:
3' Azido 2',3' dideoxythymidine
3' Azido 3' deoxythymidine
3'-Azido-2',3'-dideoxythymidine
3'-Azido-3'-deoxythymidine
Antiviral azt
Apo-Zidovudine
Azidothymidine
AZT
AZT (antiviral)
AZT antiviral
AZT, antiviral
Aztec
BW a509U
BWA 509u
BWA509u
|
BWA-509u
BW-A509U
BW-A-509U
COMPOUND S
COMPOUND-S
Novo-Azt
NSC-602670
Retrovir
ZDV
Zidovudin
Zidovudina
Zidovudine
Zidovudine EP III
Zidovudinum
|
|
14 |
|
Zalcitabine |
Approved, Investigational |
Phase 4 |
|
7481-89-2 |
24066 |
Synonyms:
2',3' Dideoxycytidine
2',3'-Dideoxycytidine
4-AMINO-1-[(2R,5S)-5-(HYDROXYMETHYL)-2-TETRAHYDROFURANYL]-2-PYRIMIDINONE
4-AMINO-1-[(2R,5S)-5-(HYDROXYMETHYL)OXOLAN-2-YL]PYRIMIDIN-2-ONE
4-Amino-1-[(2R,5S)-5-(hydroxymethyl)tetrahydrofuran-2-yl]pyrimidin-2(1H)-one
4-AMINO-1-[(2R,5S)-5-(HYDROXYMETHYL)TETRAHYDROFURAN-2-YL]PYRIMIDIN-2-ONE
4-AMINO-1-[(2R,5S)-5-METHYLOLTETRAHYDROFURAN-2-YL]PYRIMIDIN-2-ONE
4-AZANYL-1-[(2R,5S)-5-(HYDROXYMETHYL)OXOLAN-2-YL]PYRIMIDIN-2-ONE
DDC
DDC (Antiviral)
DDCYD
|
Dideoxycytidine
DIDEOXYCYTIDINE (DDC)
Hivid
HIVID roche
Hoffman-la roche brand OF zalcitabine
NSC-606170
RO-242027000
RO-24-2027000
RO-242027000/RO-24-2027-000
Roche brand OF zalcitabine
ZALCITABINE
|
|
15 |
|
Stavudine |
Approved, Investigational |
Phase 4 |
|
3056-17-5 |
18283 |
Synonyms:
1-(2,3-Dideoxy-b-D-glycero-pent-2-enofuranosyl)thymine
1-(2,3-Dideoxy-beta-D-glycero-pent-2-enofuranosyl)thymine
1-(2,3-Dideoxy-β-D-glycero-pent-2-enofuranosyl)thymine
2',3' Didehydro 3' deoxythymidine
2',3'-Didehydro-2',3'-dideoxythmidine
2',3'-Didehydro-3'-deoxythimidine
2',3'-Didehydro-3'-deoxythymidine
3'-Deoxy-2'-thymidinene
ABBR D4T
BMY-27857
Bristol-myers brand OF stavudine
Bristol-myers squibb brand OF stavudine
d4T
D-4T
|
Estavudina
Estavudina [INN-Spanish]
NSC-163661
Sanilvudine
STAVUDIN
STAVUDINE
Stavudine [Usan:Ban:Inn]
Stavudine, monosodium salt
Stavudinum
Stavudinum [INN-Latin]
STV
Zerit
ZERIT XR
Zerut XR
|
|
16 |
|
Indinavir |
Approved |
Phase 4 |
|
150378-17-9 |
5362440 |
Synonyms:
(1(1S,2R),5(S))-2,3,5-Trideoxy-N-(2,3-dihydro-2-hydroxy-1H-inden-1-yl)-5-(2-(((1,1-dimethylethyl)amino)carbonyl)-4-(3-pyridinylmethyl)-1-piperazinyl)-2-(phenylmethyl)-D-erythro-pentonamide
Compound J
Crixivan
INDINAVIR
INDINAVIR ANHYDROUS
INDINAVIR MONOHYDRATE
Indinavir sulfate
|
Indinavir sulphate
INDINAVIR SYSTEM SUITABILITY
Indinavir, sulfate (1:1)
L-735524
MK-639
Sulfate, indinavir
|
|
17 |
|
Didanosine |
Approved |
Phase 4 |
|
69655-05-6 |
50599 |
Synonyms:
2',3' Dideoxyinosine
2,3-Dideoxyinosine
2',3'-Dideoxyinosine
9-((2R,5S)-5-(Hydroxymethyl)-tetrahydrofuran-2-yl)-1H-purin-6(9H)-one
9-((2R,5S)-5-Hydroxymethyl-tetrahydro-furan-2-yl)-1,9-dihydro-purin-6-one
9-((2S,5R)-5-Hydroxymethyl-tetrahydro-furan-2-yl)-9H-purin-6-ol
9-[(2R,5S)-5-(Hydroxymethyl)tetrahydrofuran-2-yl]-1,9-dihydro-6H-purin-6-one
ABBR ddi
BMY-40900
Bristol myers brand OF didanosine
Bristol myers squibb brand OF didanosine
Bristol-myers brand OF didanosine
Bristol-myers squibb brand OF didanosine
|
DDI
DdI (antiviral)
DdIno
Didanosina
Didanosine
DIDANOSINE SYSTEM SUITABILITY MIXTURE
Didanosinum
Dideoxyinosine
DIDEOXYINOSINE (DDI)
NSC-612049
Videx
VIDEX EC
|
|
18 |
|
Tranexamic acid |
Approved |
Phase 4 |
|
1197-18-8 |
5526 |
Synonyms:
(1R,4R)-4-(AMINOMETHYL)CYCLOHEXANE-1-CARBOXYLIC ACID
Acide tranexamique
Acide tranéxamique
Acido tranexamico
ácido tranexámico
Acidum tranexamicum
CL-65336
CL-65336|Cyclo-F®|Cyklokapron®|Femstrual®|trans AMCHA
CYCLO-F
CYKLO-F HEAVY PERIOD RELIEF
Cyklokapron
EXACYL
FEMSTRUAL
LB1148
LB-1148
LYSTEDA
MENSTRALITE
|
NSC-291305
RP-18429
Tranexamate
Tranexamic acid
Tranexamsaeure
Tranexmate
Tranexmic acid
Tranhexamate
Tranhexamic acid
trans AMCHA
trans-4-(Aminomethyl)cyclohexanecarboxylate
trans-4-(Aminomethyl)cyclohexanecarboxylic acid
trans-4-AMINOMETHYLCYCLOHEXANE-1-carboxylate
trans-4-AMINOMETHYLCYCLOHEXANE-1-carboxylIC ACID
trans-Amcha
trans-Tranexamate
trans-Tranexamic acid
|
|
19 |
|
Mometasone furoate |
Approved, Investigational, Vet_approved |
Phase 4 |
|
83919-23-7 |
4240 441336 |
Synonyms:
(9BETA,10ALPHA,11ALPHA,14BETA,16ALPHA,17ALPHA)-9,21-DICHLORO-11-HYDROXY-16-METHYL-3,20-DIOXOPREGNA-1,4-DIEN-17-YL FURAN-2-CARBOXYLATE
ASMANEX
ASMANEX HFA
ASMANEX TWISTHALER
ELOCON
MOMETASONE
MOMETASONE 17-FUROATE
|
MOMETASONE FUROATE
Mometasone furoate anhydrous
MOMETASONE FUROATE MONOHYDRATE
Mometasone furoic acid
NASONEX
SCH-32088
SINUVA
|
|
20 |
|
Arginine |
Approved, Investigational, Nutraceutical |
Phase 4 |
|
74-79-3 |
6322 |
Synonyms:
(2S)-2-Amino-5-(carbamimidamido)pentanoate
(2S)-2-Amino-5-(carbamimidamido)pentanoic acid
(2S)-2-AMINO-5-(DIAMINOMETHYLIDENEAMINO)PENTANOIC ACID
(2S)-2-AMINO-5-[(DIAMINOMETHYLIDENE)AMINO]PENTANOIC ACID
(2S)-2-Amino-5-guanidinopentanoate
(2S)-2-Amino-5-guanidinopentanoic acid
(2S)-2-AMINO-5-GUANIDINO-PENTANOIC ACID
(S)-2-Amino-5-[(aminoiminomethyl)amino]pentanoate
(S)-2-Amino-5-[(aminoiminomethyl)amino]-pentanoate
(S)-2-Amino-5-[(aminoiminomethyl)amino]pentanoic acid
(S)-2-Amino-5-[(aminoiminomethyl)amino]-pentanoic acid
(S)-2-Amino-5-guanidinopentanoate
(S)-2-Amino-5-guanidinopentanoic acid
(S)-2-Amino-5-guanidinovalerate
(S)-2-Amino-5-guanidinovaleric acid
2-Amino-5-guanidinovalerate
2-Amino-5-guanidinovaleric acid
5-[(Aminoiminomethyl)amino]-L-norvaline
Arg
Arginina
Arginine
|
Arginine hydrochloride
Arginine, L isomer
Arginine, L-isomer
DL Arginine acetate, monohydrate
DL-Arginine acetate, monohydrate
Hydrochloride, arginine
L Arginine
L-(+)-Arginine
L-a-Amino-D-guanidinovalerate
L-a-Amino-D-guanidinovaleric acid
L-alpha-Amino-delta-guanidinovalerate
L-alpha-Amino-delta-guanidinovaleric acid
L-Arg
L-Arginin
L-ARGININE
L-Isomer arginine
Monohydrate DL-arginine acetate
N5-(Aminoiminomethyl)-L-ornithine
NSC-206269
R
|
|
21 |
|
Antirheumatic Agents |
|
Phase 4 |
|
|
|
22 |
|
Antineoplastic Agents, Immunological |
|
Phase 4 |
|
|
|
23 |
|
Antineoplastic Agents, Hormonal |
|
Phase 4 |
|
|
|
24 |
|
Hemostatics |
|
Phase 4 |
|
|
|
25 |
|
Triamcinolone hexacetonide |
|
Phase 4 |
|
|
|
Synonyms:
ARISTOSPAN
CL-34433
LEDERSPAN
|
TATBA
TRIAMCINOLONE HEXACETONIDE
|
|
26 |
|
Triamcinolone diacetate |
|
Phase 4 |
|
|
|
Synonyms:
ARISTOCORT
KENACORT
ORION
POLCORTOLON
|
TEDAROL
TRIAMCINOLONE 16,21-DIACETATE
TRIAMCINOLONE DIACETATE
|
|
27 |
|
Triamcinolone Acetonide |
|
Phase 4 |
|
|
6436 |
Synonyms:
ADCORTYL
ADCORTYL IN ORABASE
ALLERNAZE
ARISTOCORT
ARISTOCORT A
ARISTOGEL
AUDICORT
AUREOCORT
AZMACORT
FLUTEX
GPPE EAR DPS CAP
GPPE EAR OINT
KENACORT
KENACOURT
KENALOG
KENALOG IN ORABASE
KENALOG-10
KENALOG-40
KENALOG-80
KENALOG-H
NASACORT
NASACORT ALLERGY 24 HOUR
NASACORT AQ
|
NASACORT HFA
NSC-21916
NYSTADERMAL
ORACORT
ORALONE
PEVARYL T.C.
REMIDERM
REMOTIC
SILDERM
TRIACET
TRIACORT
TRI-ADCORTYL
TRIAMCINOLONE ACETONIDE
TRIAMCINOLONE ACETONIDE IN ABSORBASE
TRIATEX
TRIDERM
TRIESENCE
TRI-NASAL
TRIVARIS
TRYMEX
VETALOG
ZILRETTA
Zilretta®
|
|
28 |
|
Hylan |
|
Phase 4 |
|
|
|
29 |
|
Arginine Vasopressin |
|
Phase 4 |
|
|
|
30 |
|
Vasopressins |
|
Phase 4 |
|
|
|
31 |
|
Deamino Arginine Vasopressin |
|
Phase 4 |
|
|
|
32 |
|
Antiviral Agents |
|
Phase 4 |
|
|
|
33 |
|
Anti-Infective Agents |
|
Phase 4 |
|
|
|
34 |
|
Antimetabolites |
|
Phase 4 |
|
|
|
35 |
|
Reverse Transcriptase Inhibitors |
|
Phase 4 |
|
|
|
36 |
|
interferons |
|
Phase 4 |
|
|
|
37 |
|
Antifibrinolytic Agents |
|
Phase 4 |
|
|
|
38 |
|
Interferon-alpha |
|
Phase 4 |
|
|
|
39 |
|
Immunologic Factors |
|
Phase 4 |
|
|
|
40 |
|
Immunoglobulins, Intravenous |
|
Phase 4 |
|
|
|
41 |
|
Immunoglobulin Fc Fragments |
|
Phase 4 |
|
|
|
42 |
|
BAX 855 |
|
Phase 4 |
|
|
|
43 |
|
Phylloquinone |
Approved, Investigational |
Phase 3 |
|
84-80-0 |
5284607 |
Synonyms:
(2S)-2-(Henicosanoyloxy)-3-(tridecanoyloxy)propyl (7Z,10Z,19Z)-docosa-4,7,10,13,16,19-hexaenoic acid
2',3'-trans-Vitamin K1
2’,3’-trans-vitamin K1
2-Methyl-3-(3,7,11,15-tetramethyl-2-hexadecenyl)-1,4-naphthalenedione
2-Methyl-3-[(2E)-3,7,11,15-tetramethyl-2-hexadecenyl]naphthoquinone
2-METHYL-3-[(2E)-3,7,11,15-TETRAMETHYLHEXADEC-2-EN-1-YL]-1,4-DIHYDRONAPHTHALENE-1,4-DIONE
2-METHYL-3-[(2E,7R,11R)-3,7,11,15-TETRAMETHYLHEXADEC-2-EN-1-YL]NAPHTHALENE-1,4-DIONE
2-methyl-3-[(E,7R,11R)-3,7,11,15-tetramethylhexadec-2-enyl]naphthalene-1,4-dione
2-METHYL-3-PHYTHYL-1,4-NAPHTHOCHINON
2-Methyl-3-phytyl-1,4-naphthochinon
2-Methyl-3-phytyl-1,4-naphthoquinone
2-METHYL-3-PHYTYL-1,4-NAPTHOQUINONE
3-Phytylmenadione
alpha-Phylloquinone
ANTIHEMORRHAGIC VITAMIN
a-Phylloquinone
AQUA MEPHYTON
AQUA-MEPHYTIN
Aquamephyton
COMBINAL K1
Fitomenadiona
FITOMENADIONE
KANAVIT
KATIV N
KEPHTON
KINADION
K-JECT
|
Konakion
KONAKION MM
KONAKION MM PAED
MEPHYTON
MONODION
MONO-KAY
NEOKAY
NSC-270681
ORAKAY
Phyllochinon
Phyllochinonum
Phyllohydroquinone
Phylloquinone
PHYLLOQUINONE E-FORM
PHYTHYL-MENADION
Phytomenadione
Phytomenadionum
Phytonadione
Phytonadionum
Phytylmenadione
SYNTHEX P
trans-Phylloquinone
VITAMIN K
Vitamin K 1
Vitamin K hydroquinone (phylloquinone)
Vitamin K1
Α-phylloquinone
|
|
44 |
|
Cyclophosphamide |
Approved, Investigational |
Phase 2, Phase 3 |
|
50-18-0, 6055-19-2 |
2907 |
Synonyms:
(+-)-Cyclophosphamide
(+,-)-2-(Bis(2-chloroethyl)amino)tetrahydro-2H-1,3,2-oxazaphosphorine 2-oxide monohydrate
(RS)-Cyclophosphamide
2-[Bis(2-chloroethylamino)]-tetrahydro-2H-1,3,2-oxazaphosphorine-2-oxide
Anhydrous cyclophosphamide
Anhydrous, cyclophosphamide
ASTA
Asta B 518
Bis(2-chloroethyl)phosphoramide cyclic propanolamide ester
Ciclofosfamida
Ciclofosfamide
Clafen
Claphene
CP
CPA
CTX
CY
Cyclophosphamid
Cyclophosphamide
Cyclophosphamide anhydrous
Cyclophosphamide monohydrate
Cyclophosphamide Sterile
Cyclophosphamide, (R)-isomer
Cyclophosphamide, (S)-isomer
Cyclophosphamidum
Cyclophosphan
Cyclophosphane
Cyclophosphoramide
|
Cyclostin
Cyklofosfamid
Cytophosphan
Cytophosphane
Cytoxan
Cytoxan Lyoph
Endoxan
Endoxan R
Endoxana
Endoxanal
Endoxan-Asta
Endoxane
Enduxan
Genoxal
Hexadrin
LEDOXINA
Lyophilized Cytoxan
Mitoxan
Monohydrate, cyclophosphamide
N,N-Bis(2-chloroethyl)tetrahydro-2H-1,3,2-oxazaphosphorin-2-amine 2-oxide
Neosar
Procytox
Rcra Waste Number U058
Revimmune
Semdoxan
Sendoxan
Senduxan
Zyklophosphamid
|
|
45 |
|
Menadione |
Approved, Nutraceutical |
Phase 3 |
|
58-27-5 |
4055 |
Synonyms:
2-METHYL-1,4-DIHYDRONAPHTHALENE-1,4-DIONE
2-Methyl-1,4-naftochinon
2-Methyl-1,4-naphthalendione
2-Methyl-1,4-naphthalenedione
2-Methyl-1,4-naphthochinon
2-Methyl-1,4-naphthodione
2-Methyl-1,4-naphthoquinone
2-Methylnaphthoquinone
3-Methyl-1,4-naphthoquinone
Aquakay
Aquinone
Bisulfite, menadione
Bisulfite, menadione sodium
Hemodal
Juva-K
Kaergona
Kanone
Kappaxan
Kappaxin
Karcon
Kareon
Kativ-g
Kayklot
Kaykot
Kaynone
Kayquinone
Kipca
Kipca-oil soluble
Klottone
Koaxin
Kolklot
|
K-Thrombyl
K-Vitan
Menadion
MENADIONE
Menadione bisulfite
Menadione sodium bisulfite
Menadione sodium bisulfite, trihydrate
Menaphthene
Menaphthon
Menaphthone
Menaphtone
Menaquinone
Menaquinone O
Mitenon
Mitenone
MNQ
NSC-4170
Panosine
Prokayvit
Sodium bisulfite, menadione
Synkay
Thyloquinone
Vicasol
Vikasol
Vitamin K 3
Vitamin K0
Vitamin K2
Vitamin K3
Vitamin K3 sodium bisulfite
Vitamin K3: 1,4-dihydro-1,4-dioxo-2-methylnaphthalene
|
|
46 |
|
Vitamin A |
Approved, Nutraceutical, Vet_approved |
Phase 3 |
|
22737-96-8, 68-26-8 |
5280382 445354 |
Synonyms:
(2E,4E,6E,8E)-3,7-DIMETHYL-9-(2,6,6-TRIMETHYLCYCLOHEX-1-EN-1-YL)NONA-2,4,6,8-TETRAEN-1-OL
(ALL-E)-3,7-DIMETHYL-9-(2,6,6-TRIMETHYL-1-CYCLOHEXEN-1-YL)-2,4,6,8-NONATETRAEN-1-OL
11-CIS-RETINOL
11-cis-Vitamin a alcohol
3,7-Dimethyl-9-(2,6,6-trimethyl-1-cyclohexen-1-yl)-2,4,6,8-nonatetraen-1-ol, (all-e)-isomer
all trans Retinol
all-trans-Retinol
ALL-TRANS-RETINYL ALCOHOL
ALL-TRANS-VITAMIN A ALCOHOL
ALPHALIN
Aquasol a
AROVIT
BETA-RETINOL
B-RETINOL
CHOCOLA A
cis-11-Retinol
|
NEPALM
NSC-122759
OLEOVITAMIN A
Retinol
RETINOL (VIT A)
RETINOL ACETATE
RETINOL PALMITATE
Retinolum
RO-A-VIT
TRANS-RETINOL
Vitamin a
VITAMIN A 1
VITAMIN A OIL
VITAMIN A SOLUBILIZED
Vitamin a1
|
|
47 |
|
Menaquinone |
Investigational |
Phase 3 |
|
1182-68-9 |
|
48 |
|
Immunosuppressive Agents |
|
Phase 3 |
|
|
|
49 |
|
Alkylating Agents |
|
Phase 3 |
|
|
|
50 |
|
Antineoplastic Agents, Alkylating |
|
Phase 3 |
|
|
|
Interventional clinical trials:
(show top 50)
(show all 763)
# |
Name |
Status |
NCT ID |
Phase |
Drugs |
1 |
The Effectiveness of Recombinant Fusion Protein Linking Coagulation Factor IX With Recombinant Albumin (rIX-FP) in Severe Hemophilia B Patients Switching From Previous Factor IX Treatment |
Unknown status |
NCT04108260 |
Phase 4 |
Albutrepenonacog Alfa 1 UNT [IDELVION] |
2 |
DDAVP vs Exercise in Patients With Mild Hemophilia A - Which is Better and do They Work Synergistically in Improving Hemostasis? |
Unknown status |
NCT03136003 |
Phase 4 |
DDAVP |
3 |
Capital Characteristic Application: Pharmacokinetic(PK) Research on Chinese Children of Hemophilia |
Unknown status |
NCT03622476 |
Phase 4 |
concentrated FVIII |
4 |
IMMUNE TOLERANCE INDUCTION, BY FACTOR VIII CONCENTRATE CONTAINING VON WILLEBRAND FACTOR, IN SEVERE OR MODERATE HAEMOPHILIA A PATIENTS WITH INHIBITORS |
Unknown status |
NCT02479087 |
Phase 4 |
Plasma-derived FVIII/VWF concentrate |
5 |
Beijing Children's Hospital, Capital Medical University |
Unknown status |
NCT03598725 |
Phase 4 |
Coagulation Factor VIII;Prednisone;Rituximab |
6 |
Hematology Oncology Center |
Unknown status |
NCT02999308 |
Phase 4 |
|
7 |
Subclinical Joint Bleeding in Irish Adults With Severe Haemophilia A on Personalised Prophylaxis Regimens |
Unknown status |
NCT02314325 |
Phase 4 |
ADVATE [Antihemophilic Factor (Recombinant)] |
8 |
Routine Prophylaxis Treatment Versus On-demand Treatment for Children With Severe Hemophilia A: Comparison of All Bleeding Events in Chinese Hemophilia Patients |
Completed |
NCT01810666 |
Phase 4 |
|
9 |
Viscosupplementation in Patients With Hemophilic Arthropathy |
Completed |
NCT01748201 |
Phase 4 |
|
10 |
A SINGLE COUNTRY, MULTICENTER, OPEN-LABEL AND NON-RANDOMIZED CLINICAL TRIAL WITH NONACOG ALFA PROPHYLAXIS AND TREATMENT OF BLEEDING EPISODES IN PREVIOUSLY TREATED PATIENTS WITH MODERATELY-SEVERE TO SEVERE HEMOPHILIA B FOR A DURATION OF 8 WEEKS. |
Completed |
NCT04286412 |
Phase 4 |
|
11 |
Impact of Conservative Treatment by Custom-made Orthoses in Patients With Haemophilic Ankle Arthropathy |
Completed |
NCT00638001 |
Phase 4 |
|
12 |
Reformulated BeneFIX Efficacy and Safety After Conversion From a pdFIX |
Completed |
NCT00749476 |
Phase 4 |
|
13 |
NovoSeven® (rFVIIa) by Single Dose for Home Treatment of Joint Bleeds in Haemophilia Patients With Inhibitors: A Pilot, Double-Blind Study Versus Standard Multiple Doses of NovoSeven® and Open-Label FEIBA® |
Completed |
NCT00108797 |
Phase 4 |
eptacog alfa (activated);Feiba VH |
14 |
An Open-label, Single-arm, Post-authorization Pragmatic Clinical Trial On The Safety And Efficacy Of Benefix (Nonacog Alfa, Recombinant Factor Ix) In Subjects With Hemophilia B In Usual Care Settings In China |
Completed |
NCT02336178 |
Phase 4 |
Benefix |
15 |
rFVIIa (NovoSeven®) for Treatment of Mild/Moderate Joint Bleeds in Haemophilia Patients With Inhibitors: A Double-blind Study of a Single High Dose Versus Standard Multiple Doses of rFVIIa |
Completed |
NCT00571584 |
Phase 4 |
activated recombinant human factor VII |
16 |
Phase IV Multi-Center, Prospective, Interventional, Post-Marketing Study in Hemophilia B Patients in India Receiving RIXUBIS as On-demand or Prophylaxis Under Standard Clinical Practice |
Completed |
NCT03565237 |
Phase 4 |
|
17 |
Evaluation of Efficacy and Safety of Benefix®- Coagulation Factor ix, Recombinant, in Previously Treated Patients With Hemophilia b. |
Completed |
NCT00581126 |
Phase 4 |
Recombinant Factor IX Coagulation |
18 |
Post Marketing Study in Haemophilia B Patients Using Nonafact® 100 IU/ml Powder and Solvent for Solution for Injection(Human Coagulation Factor IX)(Human Plasma Derived Factor IX Product, Freeze Dried) |
Completed |
NCT00139828 |
Phase 4 |
human coagulation Factor IX |
19 |
IMMUNINE - Purified Factor IX Concentrate Virus-Inactivated: A Phase 4, Prospective, Open-label Multicenter Study to Prospectively Document the Exposure of IMMUNINE and to Monitor FIX Inhibitors in Previously Treated Patients With Severe (FIX Level < 1%) or Moderately Severe (FIX Level <= 2%) Hemophilia B Who Are Planned to Enter BAX 326 Study 250901 to Investigate a New Recombinant FIX Concentrate |
Completed |
NCT01128881 |
Phase 4 |
|
20 |
An Open-Label, Randomized, Parallel, Multicenter Trial Comparing the Safety and Efficacy of rFVIIa When Administered as i.v. Bolus or i.v. Continuous Infusion to Hemophiliacs With Inhibitors During and After Major Surgery |
Completed |
NCT01561391 |
Phase 4 |
activated recombinant human factor VII;factor VIII |
21 |
Pharmacokinetic Comparison of Advate rAHF-PFM With Recombinate rAHF in Patients With Severe Hemophilia A: a Phase IV, Prospective, Randomized, Controlled, Cross-over, Single Center Study |
Completed |
NCT00666406 |
Phase 4 |
Antihemophilic Factor (Recombinant) - Plasma/Albumin Free Method (rAHF-PFM);Recombinant Factor VIII (rAHF) |
22 |
A Prospective Study to Evaluate the Effect of rFVIII-FS in Different Prophylactic Regimens on Bleeding Events Frequency and Development of Arthropathy in Previously Treated and Minimally Treated Hemophilia A Pediatric Population. |
Completed |
NCT00632814 |
Phase 4 |
rFVIII-FS (Kogenate FS, BAY14-2222) 70 IU/kg, dosing once per week;rFVIII-FS (Kogenate FS, BAY14-2222), 70 IU/kg twice per week (30 IU/kg + 40 IU/kg);rFVIII-FS (Kogenate FS, BAY14-2222) 75 IU/kg, dosing three times per week (3 x 25 IU/kg) |
23 |
Comparison of Different Prophylaxis Regimens for Moderate to Severe Hemophilia A Pediatric Patients |
Completed |
NCT02727647 |
Phase 4 |
FVIII |
24 |
Post-marketing Investigation (PMI) to Assess Safety and Efficacy of Jivi (BAY 94-9027) Treatment in Participants With Hemophilia A |
Completed |
NCT04085458 |
Phase 4 |
Damoctocog alfa pegol (Jivi, BAY94-9027) |
25 |
A Non-controlled, Open-Label, Multicenter, Study of Efficacy of rFVIIIFc for Immune Tolerance Induction (ITI) in Severe Hemophilia A Subjects With Inhibitors Undergoing the First ITI Treatment |
Completed |
NCT03093480 |
Phase 4 |
|
26 |
An Open Label Study to Evaluate the Safety and Effect on Sustained Virological Response of PEGASYS Plus Ribavirin in Patients With Hemophilia A and Chronic Hepatitis C |
Completed |
NCT00475072 |
Phase 4 |
peginterferon alfa-2a [Pegasys];ribavirin |
27 |
A Phase IV Study of the Safety and Efficacy of ReFacto® (Moroctocog Alfa, B-Domain Deleted Recombinant Factor VIII) in Subjects With Hemophilia A Undergoing Major Surgery Monitored Using the Chromogenic Substrate Assay at the Local Laboratory |
Completed |
NCT00092976 |
Phase 4 |
ReFacto |
28 |
Pharmacokinetic Comparison of 3000 IU Advate (rAHF-PFM) (Using One 3000 IU Potency Vial) With 3000 IU Advate (rAHF PFM) (Using Two 1500 IU Potency Vials) in Previously Treated Patients With Severe Hemophilia A: a Phase 4, Open-label, Prospective, Randomized, Controlled, Crossover, Multiple Center Study |
Completed |
NCT00916032 |
Phase 4 |
|
29 |
Moderate Term Musculoskeletal Outcomes With Escalating Dose Prophylaxis: the Canadian Hemophilia Prophylaxis Study Follow-up Study |
Completed |
NCT01085344 |
Phase 4 |
|
30 |
A Diagnostic Interventional, Controlled, Cross-sectional Evaluation of Joint Status Using Magnetic Resonance Imaging in Subjects With Severe Hemophilia A Treated With Primary Prophylaxis, Secondary Prophylaxis, or On-demand Therapy |
Completed |
NCT00927667 |
Phase 4 |
|
31 |
A Non-randomized, Open-label Study To Evaluate The Pharmacokinetics, Safety And Efficacy Of Refacto Af In Previously Treated Pediatric Subjects Less Than Twelve Years Of Age With Severe Hemophilia A (Fviii:c <1%). |
Completed |
NCT00914459 |
Phase 4 |
|
32 |
A Prospective Controlled Study on the Effect on Bleeding Events and Joint Function in Young Adults With Severe Hemophilia A After a 6 Month Prophylaxis Treatment Compared to on Demand Treatment |
Completed |
NCT00586521 |
Phase 4 |
Kogenate (BAY14-2222) |
33 |
A Multiclinic, Open Pilot Study to Investigate the Effect of Combination Antiretroviral Therapy Including Indinavir Sulfate on Coagulation Factors, on Platelet Aggregation, and on Factor VIII/IX Half-Life in HIV-1 Seropositive Patients With Hemophilia A or B |
Completed |
NCT00002386 |
Phase 4 |
Indinavir sulfate;Lamivudine;Stavudine;Zidovudine;Zalcitabine;Didanosine |
34 |
A SINGLE COUNTRY, MULTICENTER, OPEN-LABEL AND NON-RANDOMIZED CLINICAL TRIAL WITH MOROCTOCOG ALFA (AF-CC) PROPHYLAXIS AND TREATMENT OF BLEEDING EPISODES IN PREVIOUSLY TREATED PATIENTS WITH MODERATE AND SEVERE HEMOPHILIA A FOR A DURATION OF 8 WEEKS |
Completed |
NCT04396639 |
Phase 4 |
|
35 |
Exercise Versus DDAVP in Patients With Mild Hemophilia A - is One Non-inferior to the Other and do They Work Additively in Improving Hemostasis? |
Completed |
NCT03379974 |
Phase 4 |
DDAVP Inhalant Product |
36 |
An Open-label, Single-arm, Post- Authorization Pragmatic Clinical Trial On The Safety And Efficacy Of Xyntha (Moroctocog-alfa (Af-cc), Recombinant Fviii) In Subjects With Hemophilia A In Usual Care Settings In China |
Completed |
NCT02492984 |
Phase 4 |
Intravenous infusions of Xyntha |
37 |
Antihemophilic Factor (Recombinant) Plasma/Albumin-Free Method (rAHF PFM): A Phase 3/4, Prospective, Controlled, Randomized, Multi-Center Study to Compare the Efficacy and Safety of Continuous Infusion (CI) Versus Intermittent Bolus Infusion (BI) in Subjects With Severe or Moderately Severe Hemophilia A Undergoing Major Orthopedic Surgery |
Completed |
NCT00357656 |
Phase 4 |
Recombinant Protein-Free Factor VIII (rAHF-PFM) |
38 |
Phase IV A Study of Immunologic Safety for Alphanate in Previously Treated Patients Diagnosed With Severe Hemophilia A |
Completed |
NCT00323856 |
Phase 4 |
Alphanate SD/HT |
39 |
Advate Antihemophilic Factor (Recombinant), Plasma/Albumin-Free Method (ADVATE rAHF-PFM): A Phase 4 Study to Determine the Pharmacokinetic Response of Patients Diagnosed With Severe Hemophilia A to Different Doses of ADVATE rAHF-PFM |
Completed |
NCT00289536 |
Phase 4 |
|
40 |
Combination Therapy of Low Doses of rFVIIa and FEIBA for Severe Hemophilia A Patients With an Inhibitor to Factor VIII |
Completed |
NCT00284193 |
Phase 4 |
rFVIIa-FEIBA therapy for hemophilia A inhibitors;FEIBA- Activated Prothrombin Complexes |
41 |
Advate Antihemophilic Factor (Recombinant), Plasma/Albumin Free Method (ADVATE rAHF-PFM): A Phase 4 Study Comparing Two Prophylactic Regimens in Subjects With Severe or Moderately Severe Hemophilia A |
Completed |
NCT00243386 |
Phase 4 |
Antihemophilic factor, recombinant, manufactured protein-free |
42 |
Study to Evaluate Efficacy and Safety of ADVATE in the Treatment of Previously Treated Patients With Hemophilia A |
Completed |
NCT02170402 |
Phase 4 |
|
43 |
Optimizing the Use of Prophylaxis in Patients With Severe Haemophilia A Using PK Measurement (myPKFiT) |
Completed |
NCT03915080 |
Phase 4 |
Oktokog alpha |
44 |
A Non-Controlled, Open-Label, Multicenter, Study of Immune Tolerance Induction Performed With rFVIIIFc Within a Timeframe of 60 Weeks in Severe Haemophilia A Patients With Inhibitors Who Have Failed Previous Immune Tolerance Induction Therapies |
Completed |
NCT03103542 |
Phase 4 |
|
45 |
A Study on PEGASYS® (Peginterferon Alfa-2a (40KD)) Plus COPEGUS® (Ribavirin) in Iranian Hemophilic Patients With Chronic Hepatitis C Infection |
Completed |
NCT00707772 |
Phase 4 |
PEGASYS® (Peginterferon Alfa-2a (40KD)) Plus COPEGUS® (Ribavirin) |
46 |
AN OPEN-LABEL STUDY OF THE SAFETY AND EFFICACY OF REFACTO AF IN PREVIOUSLY UNTREATED PATIENTS IN USUAL CARE SETTINGS |
Completed |
NCT00950170 |
Phase 4 |
|
47 |
Clinical Outcomes of Low Dose Pharmacokinetic-guided Extended Half-life FVIII Concentrates Versus Low Dose Standard Prophylaxis in Thai Severe Haemophilia A Patients |
Completed |
NCT05281185 |
Phase 4 |
Extended half-life FVIII concentrates with PK-guided dosing;standard half-life FVIII concentrates with weight-based dosing |
48 |
Inhibitor Development in Previously Untreated Patients (PUPs) or Minimally Blood Component-Treated Patients (MBCTPs) When Exposed to Plasma-derived Von Willebrand Factor-Containing Factor VIII (VWF/FVIII) Concentrates and to Recombinant Factor VIII (rFVIII) Concentrates: An Independent, International, Multicentre, Prospective, Controlled, Randomised, Open Label, Clinical Trial |
Completed |
NCT01064284 |
Phase 4 |
PLASMA DERIVED Factor VIII;Recombinant FVIII |
49 |
Efficacy and Cost Effectiveness of Standard Versus Pharmacokinetic Dosing During Factor VIII Prophylaxis in Adult Patients With Severe Haemophilia A |
Completed |
NCT02697370 |
Phase 4 |
Pharmacokinetic based dosage change |
50 |
Study of Safety and Efficacy of Antihemophilic Factor/Von Willebrand Factor Complex (Humate-P®) Using Individualized Dosing in Pediatric and Adult Surgical Subjects With Von Willebrand's Disease. |
Completed |
NCT00168090 |
Phase 4 |
Blood coagulation Factor VIII and vWF, human |
Inferred drug relations via
UMLS
71
/
NDF-RT
50
:
antihemophilic factor, human
Antihemophilic Factor, Human Recombinant
Antihemophilic factor, porcine
ANTIHEMOPHILIC FACTOR,HUMAN,METHOD M,MONOCLONAL
|
Factor VIII
nonacog alfa
recombinant FVIIa
|
|